StayBred requires FDA approval or ANDA filing
Company: Riot
The claim, verbatim
FDA approval is required prior to sale of StayBred unless sold through compounding pharmacies after ANDA filing
Source (primary)
Riot SB-2 filed 2004-09-14 (SEC EDGAR, sec_filing)
View cached copy (2026-09-27)Live source ↗
Quote: “FDA approval is required prior to the sale of StayBred unless it is sold thru compounding pharmacies after an ANDA has been filed.”
How we checked this
Checked on September 30, 2026. The cited source supports every part of this claim.
The filing states that StayBred needs FDA approval before sale unless it is sold through compounding pharmacies after an ANDA has been filed.
Confirmed in the source:
- FDA approval is required before StayBred can be sold
- The exception is sale through compounding pharmacies after an ANDA has been filed
What we did: Read our cached copy of SEC EDGAR (https://www.sec.gov/Archives/edgar/data/1167419/000107997304000468/aspenbio_sb2.txt) in full (272,234 characters, retrieved September 27, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms Riot SB-2 filed 2004-09-14
Quote: “FDA approval is required prior to the sale of StayBred unless it is sold thru compounding pharmacies after an ANDA has been filed.”